Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): Efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors Meeting Abstract
| Authors: | Munir, T.; Hillmen, P.; Sharman, J.; Coutre, S.; Furman, R.; Cheson, B.; Pagel, J.; Barrientos, J.; Zelenetz, A.; Kipps, T.; Flinn, I.; Ghia, P.; Hallek, M.; Coiffier, B.; O'Brien, S.; Tausch, E.; Kreuzer, K.; Jiang, W.; Lazarov, M.; Li, D.; Jahn, T.; Stilgenbauer, S. |
| Abstract Title: | Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): Efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors |
| Meeting Title: | 55th Annual Scientific Meeting of the British Society for Haematology |
| Journal Title: | British Journal of Haematology |
| Volume: | 169 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2015 Apr 20-22 |
| Meeting Location: | Edinburgh, UK |
| ISSN: | 0007-1048 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2015-04-01 |
| Start Page: | 19 |
| Language: | English |
| ACCESSION: | WOS:000353231200035 |
| PROVIDER: | wos |
| PUBMED: | 25891202 |
| DOI: | 10.1111/bjh.13350 |
| Notes: | Meeting Abstract: 34 -- 55th Annual Scientific Meeting of the British-Society-for-Haematology -- APR 20-22, 2015 -- Edinburgh, SCOTLAND -- SI -- Source: Wos |
